Skip to content

Clinical outcomes and influencing factors in patients with hypertrophic cardiomyopathy: based on case records and follow-up studies

Clinical outcomes and influencing factors in patients with hypertrophic cardiomyopathy: based on case records and follow-up studies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021454
Enrollment
Unknown
Registered
2019-02-22
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy

Interventions

Case series:No Intervention

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Echocardiography confirmed the diastolic ventricular septal thickness of 15mm or the ratio of the posterior wall thickness = 1.3.

Exclusion criteria

Exclusion criteria: 1. Combined with severe heart valve disease; 2. Combined with severe congenital heart disease (such as atrial septal defect, ventricular septal defect); 3. Multiple system diseases; 4. Rheumatic heart disease; 5. Combined with hyperdynamic heart disease such as hyperthyroidism and anemia; 6. Combined with pulmonary heart disease; 7. Hypertensive cardiomyopathy; 8. Severe hypotension (SBP 160 mmHg, and / or DBP > 100 mmHg); 10. Hepatic insufficiency (defined as ALT or total bilirubin greater than 3 times the upper limit of normal); 11. Renal dysfunction (defined as serum creatinine greater than 1.5 times the upper limit of normal); 12. Chronic obstructive pulmonary disease; 13. Active peptic ulcer and skin ulcers; 14. Those who do not have legal capacity or limited legal capacity.

Design outcomes

Primary

MeasureTime frame
Rehospitalization;All-cause death;Cardiac death;

Secondary

MeasureTime frame
The change in the activity tolerance from baseline;Major cardiac adverse events: including all-cause death, cardiogenic death, arrhythmia, etc.;

Countries

China

Contacts

Public ContactJinying Zhang

1 Jianshe Road East, Erqi District, Zhengzhou, Henan

jyzhang@zzu.edu.cn+86 13503830283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026